Literature DB >> 18400918

Caspofungin disk diffusion breakpoints and quality control.

Steven D Brown1, Maria M Traczewski.   

Abstract

Interpretive disk diffusion breakpoints for caspofungin are proposed by evaluating 762 isolates of Candida spp., representing 10 different species obtained as part of the caspofungin clinical trials. Standardized broth microdilution reference tests were compared to the zone diameters observed with 5-microg caspofungin disks produced by two different disk manufacturers. Disk diffusion breakpoints of >or=11 mm for susceptible are proposed. Compared to results from MIC testing, these zone diameters produced error rates that were <or=0.3% for all categories. In addition, an eight-laboratory disk diffusion quality control (QC) study was performed, and QC ranges are proposed for the four QC strains recommended by the CLSI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18400918      PMCID: PMC2446870          DOI: 10.1128/JCM.00279-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Guidelines for treatment of candidiasis.

Authors:  Peter G Pappas; John H Rex; Jack D Sobel; Scott G Filler; William E Dismukes; Thomas J Walsh; John E Edwards
Journal:  Clin Infect Dis       Date:  2003-12-19       Impact factor: 9.079

2.  In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.

Authors:  J A Vazquez; M Lynch; D Boikov; J D Sobel
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

3.  In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions.

Authors:  P W Nelson; M Lozano-Chiu; J H Rex
Journal:  J Med Vet Mycol       Date:  1997 Jul-Aug

4.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

Authors:  J H Rex; T J Walsh; J D Sobel; S G Filler; P G Pappas; W E Dismukes; J E Edwards
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

5.  Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

Authors:  G K Abruzzo; A M Flattery; C J Gill; L Kong; J G Smith; V B Pikounis; J M Balkovec; A F Bouffard; J F Dropinski; H Rosen; H Kropp; K Bartizal
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study.

Authors:  T L Gavan; R N Jones; A L Barry; P C Fuchs; E H Gerlach; J M Matsen; L B Reller; C Thornsberry; L D Thrupp
Journal:  J Clin Microbiol       Date:  1981-07       Impact factor: 5.948

7.  Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice.

Authors:  G K Abruzzo; C J Gill; A M Flattery; L Kong; C Leighton; J G Smith; V B Pikounis; K Bartizal; H Rosen
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

8.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

9.  In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.

Authors:  M A Pfaller; L Boyken; R J Hollis; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

10.  Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis.

Authors:  Steve Hernandez; José L López-Ribot; Laura K Najvar; Dora I McCarthy; Rosie Bocanegra; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

View more
  3 in total

Review 1.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

2.  Evaluation of CLSI M44-A2 disk diffusion and associated breakpoint testing of caspofungin and micafungin using a well-characterized panel of wild-type and fks hot spot mutant Candida isolates.

Authors:  Maiken Cavling Arendrup; Steven Park; Steven Brown; Michael Pfaller; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

3.  Emergence of azole-resistant Candida species in AIDS patients with oropharyngeal candidiasis in Iran.

Authors:  F Katiraee; F Teifoori; M Soltani
Journal:  Curr Med Mycol       Date:  2015-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.